CD44v6 as innovative sarcoma target for CAR-redirected CIK cells [PDF]
OncoImmunology, 2018 Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6.
Ymera Pignochino +2 more
exaly +8 more sources
Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches [PDF]
Cancer Immunology, ImmunotherapyOn April 7, 2025, the 2nd International CIK Cell Conference was held in Monza, Italy, marking the establishment of the International Society for CIK Cells (ISCC).
Amit Sharma +11 more
doaj +7 more sources
Cytokine-induced killer (CIK) Cells-associated transcriptome signature reveals the potential immunomodulatory role of TNFSF14 in clear cell renal cell carcinoma [PDF]
Cancer Immunology, ImmunotherapyAmong adoptive immune cell therapies, cytokine-induced killer cell (CIK) therapy has demonstrated clear therapeutic relevance in multiple cancers, particularly clear cell renal cell carcinoma (ccRCC).
Yinhao Chen +9 more
doaj +2 more sources
Dendritic Cell-Cytokine-Induced Killer Cells Co-Loaded with WT1/MUC1/Poly(I:C) Enhance Antitumor Immune Responses In Vitro and In Vivo [PDF]
BiomoleculesDendritic cell-cytokine-induced killer (DC-CIK) therapy faces limitations due to antigenic heterogeneity and suboptimal immune activation. In this study, we developed a multi-antigen-loaded DC-CIK (Ag-DC-CIK) system that co-targets Wilms’ tumor 1 (WT1 ...
Huimin Liu +6 more
doaj +2 more sources
Cytokine-induced killer cells combined with temozolomide suppress glioblastoma progression in an orthotopic model and demonstrate clinical feasibility in recurrent glioblastoma [PDF]
Frontiers in NeurologyIntroductionGlioblastoma (GBM) remains an aggressive primary brain tumor with limited therapeutic options after recurrence. Cytokine-induced killer (CIK) cells are ex vivo-expanded cytotoxic lymphocytes with T-cell and natural killer-like properties.
Young Kyu Park +7 more
doaj +2 more sources
PLoS ONE, 2023 Background Cytokine-induced killer (CIK) cells are heterogeneous lymphocytes from human peripheral blood mononucleated cells (PBMCs) co-cultured with several cytokines.
Chan-Keng Yang +6 more
doaj +2 more sources
Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer
Pathology and Oncology Research, 2023 Background: The therapeutic efficacy of cytokine-induced killer (CIK) cells versus dendritic cells (DC) co-cultured with CIK cells (DC-CIK) in treating esophageal cancer (EC) remains unclear due to the absence of a direct comparison of these two regimens.
Jiayang Sun +3 more
doaj +1 more source
Frontiers in Immunology, 2021 Cytokine-induced killer (CIK) cells are an ex vivo expanded heterogeneous cell population with an enriched NK-T phenotype (CD3+CD56+). Due to the convenient and relatively inexpensive expansion capability, together with low incidence of graft versus host
Xiaolong Wu +7 more
doaj +1 more source
BMC Immunology, 2023 Background Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing ...
Yi-Yen Lee +8 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2023 Background The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) is increasing.
Jun Li +9 more
doaj +1 more source